Genetic factors affecting patient responses to pancreatic cancer treatment (EN)

Syrigos, Konstantinos

Fotopoulos, George

Saif, Muhammad Wasif

Cancer of the exocrine pancreas is a malignancy with a high lethal rate. Surgical resection is the only possible curative mode of treatment. Metastatic pancreatic cancer is incurable with modest results from the current treatment options. New genomic information could prove treatment efficacy. An independent review of PubMed and ScienceDirect databases was performed up to March 2016, using combinations of terms such pancreatic exocrine cancer, chemotherapy, genomic profile, pancreatic cancer pharmacogenomics, genomics, molecular pancreatic pathogenesis, and targeted therapy. Recent genetic studies have identified new markers and therapeutic targets. Our current knowledge of pancreatic cancer genetics must be further advanced to elucidate the molecular basis and pathogenesis of the disease, improve the accuracy of diagnosis, and guide tailor-made therapies.Keywords Chemotherapy, genomics, molecular pancreatic pathogenesis, pancreatic exocrine cancer, targeted therapyAnn Gastroenterol 2016; 29 (4): 466-476 (EN)

info:eu-repo/semantics/article

info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία

Annals of Gastroenterology

Review Articles

Αγγλική γλώσσα

2016-09-29

http://www.annalsgastro.gr/index.php/annalsgastro/article/view/2720

Hellenic Society of Gastroenterology (EN)

1792-7463

1108-7471

Annals of Gastroenterology; Volume 29, No 4 (2016); 466 (EN)